PainReform (PRFX) Competitors $1.69 +0.06 (+3.68%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$1.68 -0.01 (-0.36%) As of 08/22/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRFX vs. TAOX, GOVX, XFOR, PHXM, HOOK, LGVN, SNPX, PHIO, IBIO, and BCDAShould you be buying PainReform stock or one of its competitors? The main competitors of PainReform include Synaptogenix (TAOX), GeoVax Labs (GOVX), X4 Pharmaceuticals (XFOR), PHAXIAM Therapeutics (PHXM), HOOKIPA Pharma (HOOK), Longeveron (LGVN), Synaptogenix (SNPX), Phio Pharmaceuticals (PHIO), iBio (IBIO), and BioCardia (BCDA). These companies are all part of the "pharmaceutical products" industry. PainReform vs. Its Competitors Synaptogenix GeoVax Labs X4 Pharmaceuticals PHAXIAM Therapeutics HOOKIPA Pharma Longeveron Synaptogenix Phio Pharmaceuticals iBio BioCardia PainReform (NASDAQ:PRFX) and Synaptogenix (NASDAQ:TAOX) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability. Which has stronger valuation & earnings, PRFX or TAOX? Synaptogenix is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPainReformN/AN/A-$14.59M-$147.33-0.01SynaptogenixN/AN/A-$12.77M-$20.16-0.38 Does the media prefer PRFX or TAOX? In the previous week, PainReform had 5 more articles in the media than Synaptogenix. MarketBeat recorded 6 mentions for PainReform and 1 mentions for Synaptogenix. PainReform's average media sentiment score of 0.76 beat Synaptogenix's score of 0.00 indicating that PainReform is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PainReform 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Synaptogenix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate PRFX or TAOX? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PainReform 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Synaptogenix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders believe in PRFX or TAOX? 37.3% of PainReform shares are held by institutional investors. Comparatively, 10.3% of Synaptogenix shares are held by institutional investors. 34.4% of PainReform shares are held by company insiders. Comparatively, 2.7% of Synaptogenix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is PRFX or TAOX more profitable? PainReform's return on equity of 0.00% beat Synaptogenix's return on equity.Company Net Margins Return on Equity Return on Assets PainReformN/A N/A N/A Synaptogenix N/A -277.76%-150.79% Which has more risk & volatility, PRFX or TAOX? PainReform has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500. Comparatively, Synaptogenix has a beta of 1.87, indicating that its stock price is 87% more volatile than the S&P 500. SummaryPainReform beats Synaptogenix on 8 of the 11 factors compared between the two stocks. Get PainReform News Delivered to You Automatically Sign up to receive the latest news and ratings for PRFX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRFX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRFX vs. The Competition Export to ExcelMetricPainReformMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.40M$2.54B$5.83B$9.78BDividend YieldN/A1.67%4.40%4.05%P/E Ratio-0.015.4322.8124.74Price / SalesN/A752.08473.17122.93Price / CashN/A179.1038.0259.36Price / Book0.815.939.536.60Net Income-$14.59M$31.83M$3.26B$265.65M7 Day Performance25.19%1.89%2.14%2.02%1 Month Performance13.42%1.33%2.81%-0.32%1 Year Performance58.24%8.84%30.70%19.06% PainReform Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRFXPainReform1.3131 of 5 stars$1.69+3.7%N/A+57.8%$3.40MN/A-0.014TAOXSynaptogenixN/A$7.88+6.6%N/AN/A$10.95MN/A-0.784Earnings ReportGap UpGOVXGeoVax Labs1.849 of 5 stars$0.68+0.0%$8.88+1,205.3%-89.5%$10.83M$3.95M-0.3410Short Interest ↑Gap UpXFORX4 Pharmaceuticals4.1665 of 5 stars$1.84+29.2%$72.33+3,841.9%-82.8%$10.80M$2.56M-0.1380Analyst RevisionHigh Trading VolumePHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58MN/A0.0049HOOKHOOKIPA Pharma2.772 of 5 stars$0.86+4.8%$4.50+423.3%-83.0%$10.48M$9.35M-0.15160LGVNLongeveron3.5406 of 5 stars$0.68-1.6%$8.67+1,167.1%-69.6%$10.32M$2.39M-0.1120SNPXSynaptogenixN/A$7.39+20.0%N/A+72.9%$10.27MN/A-0.734Gap UpHigh Trading VolumePHIOPhio Pharmaceuticals2.888 of 5 stars$2.12-0.5%$14.00+560.4%-31.7%$10.18MN/A-0.3310Analyst DowngradeGap UpIBIOiBio1.8709 of 5 stars$0.58-1.6%$5.00+766.6%-60.3%$9.60M$375K0.00100News CoverageGap DownBCDABioCardia3.2309 of 5 stars$1.75+4.1%$25.00+1,329.4%-29.3%$9.57M$60K-0.7540 Related Companies and Tools Related Companies TAOX Competitors GOVX Competitors XFOR Competitors PHXM Competitors HOOK Competitors LGVN Competitors SNPX Competitors PHIO Competitors IBIO Competitors BCDA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRFX) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PainReform Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share PainReform With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access